These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36545807)

  • 1. Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme).
    Kiyosue A; Dunn JP; Cui X; Hickey A; Hirase T; Imaoka T; Heine RJ
    Diabetes Obes Metab; 2023 Apr; 25(4):1056-1067. PubMed ID: 36545807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
    Ma J; Liu M; Wang R; Du L; Ji L
    Diabetes Obes Metab; 2024 Apr; 26(4):1454-1463. PubMed ID: 38302718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
    Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Del Prato S; Kahn SE; Pavo I; Weerakkody GJ; Yang Z; Doupis J; Aizenberg D; Wynne AG; Riesmeyer JS; Heine RJ; Wiese RJ;
    Lancet; 2021 Nov; 398(10313):1811-1824. PubMed ID: 34672967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
    Inagaki N; Takeuchi M; Oura T; Imaoka T; Seino Y
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):623-633. PubMed ID: 35914543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
    Zeitler P; Galindo RJ; Davies MJ; Bergman BK; Thieu VT; Nicolay C; Allen S; Heine RJ; Lee CJ
    Diabetes Care; 2024 Jun; 47(6):1056-1064. PubMed ID: 38639997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).
    Yabe D; Kawamori D; Seino Y; Oura T; Takeuchi M
    Diabetes Obes Metab; 2023 Feb; 25(2):398-406. PubMed ID: 36184780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.
    Frías JP; Galindo RJ; Wang H; Malik RE; Chivukula KK; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jan; 109(2):557-568. PubMed ID: 37602701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.
    Pedersen SD; Giorgino F; Umpierrez G; Thieu VT; Rodríguez A; Nicolay C; Fernández Landó L; Karanikas CA; Kiljanski J
    Diabetes Obes Metab; 2023 Sep; 25(9):2553-2560. PubMed ID: 37246796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
    Heerspink HJL; Sattar N; Pavo I; Haupt A; Duffin KL; Yang Z; Wiese RJ; Tuttle KR; Cherney DZI
    Lancet Diabetes Endocrinol; 2022 Nov; 10(11):774-785. PubMed ID: 36152639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.
    Bi Y; Lu S; Tang J; Du L; Ji L
    Diabetes Ther; 2024 May; 15(5):1125-1137. PubMed ID: 38494574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
    Frias JP; De Block C; Brown K; Wang H; Thomas MK; Zeytinoglu M; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1745-1753. PubMed ID: 38252888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
    Lingvay I; Mosenzon O; Brown K; Cui X; O'Neill C; Fernández Landó L; Patel H
    Cardiovasc Diabetol; 2023 Mar; 22(1):66. PubMed ID: 36964557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.